BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1784 related articles for article (PubMed ID: 22541435)

  • 21. CXCR2 signaling regulates KRAS(G¹²D)-induced autocrine growth of pancreatic cancer.
    Purohit A; Varney M; Rachagani S; Ouellette MM; Batra SK; Singh RK
    Oncotarget; 2016 Feb; 7(6):7280-96. PubMed ID: 26771140
    [TBL] [Abstract][Full Text] [Related]  

  • 22. KrasG12D-induced IKK2/β/NF-κB activation by IL-1α and p62 feedforward loops is required for development of pancreatic ductal adenocarcinoma.
    Ling J; Kang Y; Zhao R; Xia Q; Lee DF; Chang Z; Li J; Peng B; Fleming JB; Wang H; Liu J; Lemischka IR; Hung MC; Chiao PJ
    Cancer Cell; 2012 Jan; 21(1):105-20. PubMed ID: 22264792
    [TBL] [Abstract][Full Text] [Related]  

  • 23. BCAT2-mediated BCAA catabolism is critical for development of pancreatic ductal adenocarcinoma.
    Li JT; Yin M; Wang D; Wang J; Lei MZ; Zhang Y; Liu Y; Zhang L; Zou SW; Hu LP; Zhang ZG; Wang YP; Wen WY; Lu HJ; Chen ZJ; Su D; Lei QY
    Nat Cell Biol; 2020 Feb; 22(2):167-174. PubMed ID: 32029896
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Ribonucleoprotein HNRNPA2B1 interacts with and regulates oncogenic KRAS in pancreatic ductal adenocarcinoma cells.
    Barceló C; Etchin J; Mansour MR; Sanda T; Ginesta MM; Sanchez-Arévalo Lobo VJ; Real FX; Capellà G; Estanyol JM; Jaumot M; Look AT; Agell N
    Gastroenterology; 2014 Oct; 147(4):882-892.e8. PubMed ID: 24998203
    [TBL] [Abstract][Full Text] [Related]  

  • 25. KRAS-regulated glutamine metabolism requires UCP2-mediated aspartate transport to support pancreatic cancer growth.
    Raho S; Capobianco L; Malivindi R; Vozza A; Piazzolla C; De Leonardis F; Gorgoglione R; Scarcia P; Pezzuto F; Agrimi G; Barile SN; Pisano I; Reshkin SJ; Greco MR; Cardone RA; Rago V; Li Y; Marobbio CMT; Sommergruber W; Riley CL; Lasorsa FM; Mills E; Vegliante MC; De Benedetto GE; Fratantonio D; Palmieri L; Dolce V; Fiermonte G
    Nat Metab; 2020 Dec; 2(12):1373-1381. PubMed ID: 33230296
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A genetically engineered mouse model developing rapid progressive pancreatic ductal adenocarcinoma.
    Yamaguchi T; Ikehara S; Nakanishi H; Ikehara Y
    J Pathol; 2014 Oct; 234(2):228-38. PubMed ID: 25042889
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Tumor Microenvironment Remodeling Enables Bypass of Oncogenic KRAS Dependency in Pancreatic Cancer.
    Hou P; Kapoor A; Zhang Q; Li J; Wu CJ; Li J; Lan Z; Tang M; Ma X; Ackroyd JJ; Kalluri R; Zhang J; Jiang S; Spring DJ; Wang YA; DePinho RA
    Cancer Discov; 2020 Jul; 10(7):1058-1077. PubMed ID: 32341020
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A novel protein RASON encoded by a lncRNA controls oncogenic RAS signaling in KRAS mutant cancers.
    Cheng R; Li F; Zhang M; Xia X; Wu J; Gao X; Zhou H; Zhang Z; Huang N; Yang X; Zhang Y; Shen S; Kang T; Liu Z; Xiao F; Yao H; Xu J; Yan C; Zhang N
    Cell Res; 2023 Jan; 33(1):30-45. PubMed ID: 36241718
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Autophagy-dependent ferroptosis drives tumor-associated macrophage polarization via release and uptake of oncogenic KRAS protein.
    Dai E; Han L; Liu J; Xie Y; Kroemer G; Klionsky DJ; Zeh HJ; Kang R; Wang J; Tang D
    Autophagy; 2020 Nov; 16(11):2069-2083. PubMed ID: 31920150
    [No Abstract]   [Full Text] [Related]  

  • 30. Elimination of oncogenic KRAS in genetic mouse models eradicates pancreatic cancer by inducing FAS-dependent apoptosis by CD8
    Mahadevan KK; LeBleu VS; Ramirez EV; Chen Y; Li B; Sockwell AM; Gagea M; Sugimoto H; Sthanam LK; Tampe D; Zeisberg M; Ying H; Jain AK; DePinho RA; Maitra A; McAndrews KM; Kalluri R
    Dev Cell; 2023 Sep; 58(17):1562-1577.e8. PubMed ID: 37625403
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Important role of Nfkb2 in the Kras
    Hassan Z; Schneeweis C; Wirth M; Müller S; Geismann C; Neuß T; Steiger K; Krämer OH; Schmid RM; Rad R; Arlt A; Reichert M; Saur D; Schneider G
    Pancreatology; 2021 Aug; 21(5):912-919. PubMed ID: 33824054
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Spontaneous induction of murine pancreatic intraepithelial neoplasia (mPanIN) by acinar cell targeting of oncogenic Kras in adult mice.
    Habbe N; Shi G; Meguid RA; Fendrich V; Esni F; Chen H; Feldmann G; Stoffers DA; Konieczny SF; Leach SD; Maitra A
    Proc Natl Acad Sci U S A; 2008 Dec; 105(48):18913-8. PubMed ID: 19028870
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Glutamine supports pancreatic cancer growth through a KRAS-regulated metabolic pathway.
    Son J; Lyssiotis CA; Ying H; Wang X; Hua S; Ligorio M; Perera RM; Ferrone CR; Mullarky E; Shyh-Chang N; Kang Y; Fleming JB; Bardeesy N; Asara JM; Haigis MC; DePinho RA; Cantley LC; Kimmelman AC
    Nature; 2013 Apr; 496(7443):101-5. PubMed ID: 23535601
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Targeting eIF4A-Dependent Translation of KRAS Signaling Molecules.
    Singh K; Lin J; Lecomte N; Mohan P; Gokce A; Sanghvi VR; Jiang M; Grbovic-Huezo O; Burčul A; Stark SG; Romesser PB; Chang Q; Melchor JP; Beyer RK; Duggan M; Fukase Y; Yang G; Ouerfelli O; Viale A; de Stanchina E; Stamford AW; Meinke PT; Rätsch G; Leach SD; Ouyang Z; Wendel HG
    Cancer Res; 2021 Apr; 81(8):2002-2014. PubMed ID: 33632898
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Aurora A kinase and its activator TPX2 are potential therapeutic targets in KRAS-induced pancreatic cancer.
    Gomes-Filho SM; Dos Santos EO; Bertoldi ERM; Scalabrini LC; Heidrich V; Dazzani B; Levantini E; Reis EM; Bassères DS
    Cell Oncol (Dordr); 2020 Jun; 43(3):445-460. PubMed ID: 32193808
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Lunatic Fringe is a potent tumor suppressor in Kras-initiated pancreatic cancer.
    Zhang S; Chung WC; Xu K
    Oncogene; 2016 May; 35(19):2485-95. PubMed ID: 26279302
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Early elevations of RAS protein level and activity are critical for the development of PDAC in the context of inflammation.
    Ma J; Gong F; Kim E; Du JX; Leung C; Song Q; Logsdon CD; Luo Y; Li X; Lu W
    Cancer Lett; 2024 Apr; 586():216694. PubMed ID: 38307409
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Inactivation of TIF1gamma cooperates with Kras to induce cystic tumors of the pancreas.
    Vincent DF; Yan KP; Treilleux I; Gay F; Arfi V; Kaniewski B; Marie JC; Lepinasse F; Martel S; Goddard-Leon S; Iovanna JL; Dubus P; Garcia S; Puisieux A; Rimokh R; Bardeesy N; Scoazec JY; Losson R; Bartholin L
    PLoS Genet; 2009 Jul; 5(7):e1000575. PubMed ID: 19629168
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Targeting Glucose Metabolism Sensitizes Pancreatic Cancer to MEK Inhibition.
    Yan L; Tu B; Yao J; Gong J; Carugo A; Bristow CA; Wang Q; Zhu C; Dai B; Kang Y; Han L; Feng N; Jin Y; Fleming J; Heffernan TP; Yao W; Ying H
    Cancer Res; 2021 Aug; 81(15):4054-4065. PubMed ID: 34117030
    [TBL] [Abstract][Full Text] [Related]  

  • 40. PIN1 Maintains Redox Balance via the c-Myc/NRF2 Axis to Counteract Kras-Induced Mitochondrial Respiratory Injury in Pancreatic Cancer Cells.
    Liang C; Shi S; Liu M; Qin Y; Meng Q; Hua J; Ji S; Zhang Y; Yang J; Xu J; Ni Q; Li M; Yu X
    Cancer Res; 2019 Jan; 79(1):133-145. PubMed ID: 30355620
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 90.